Pulmonary arterial hypertension: management in specific medical conditions
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2018, Vol 3, Issue 6
Abstract
Pulmonary arterial hypertension (PAH) is a severe and progressive disease. Due to the narrowing of the blood vessels in the lungs, pul- monary vascular resistance and pulmonary pressures increase. This results in reduced cardiac output, right heart failure and ultimately in death. Pulmonary hypertension, particularly PAH, is an independent risk factor for both peri-operative complications and post-operative mortality. The peri-operative management of patients with PAH is particularly challenging and requires a multidisciplinary approach. Appropriate patient preparation requires an accurate assessment of the severity of pulmonary hypertension, comorbidities and the type of surgery to be performed. Additionally, patients with PAH are more likely to develop an infection, particularly of the respiratory system. Infections are important risk factors for disease exacerbation, often affecting prognosis. For this reason, there is a need for effective prophylactic, diagnostic and rapid therapeutic strategies in PAH patients admitted with suspected infection. While pregnancy is not con- sidered a disease, it is associated with a significant mortality and morbidity risk in patients with PAH and therefore it is contraindicated in this group. Thus, the proper education of patients and effective contraception are necessary in order to minimize health risks. If a woman decides to maintain her pregnancy, careful monitoring, specific treatment optimization and close co-operation with an obstetrician are needed. The proper assessment of the severity of PAH and the optimization of specific treatments are crucial to improve the prognosis of PAH patients in all high-risk conditions. Additionally, the early diagnosis of high-risk conditions allows for early intensive treatment or control, which should be performed at a PAH treatment referral centre. JRCD 2018; 3 (6): 194–198.
Authors and Affiliations
Sylwia Iwańczyk, Tatiana Mularek-Kubzdela
Keywords
Related Articles
- EP ID EP286456
- DOI 10.20418/jrcd.vol3no6.320
- Views 103
- Downloads 0
Exercise capacity in adult patients after Fontan procedure. (RCD code: IV-5B.1)
Background: The aim of Fontan procedure is to restore a balance between pulmonary and systemic circulation and improve or nearly normalize arterial saturation in patients with functionally univentricular heart. Neverthel...
1st International Conference on Rare Cardiovascular Diseases (Krakow, October 18–19, 2012)
Doctors, like other academic professionals, know very well that there is no better place than a live conference to share knowledge and experience or to interact with people of similar interests.Encouraged by the success...
Long QT syndrome type 2 – can alarm clock really kill? (RCD code: V-1A.2)
This paper’s aim was to critically analyze existing research supporting statement found in many review articles that auditory stimuli may specifically and exclusively trigger cardiac events in patients with type 2 of con...
Doxorubicin cardiomyopathy – case report and review of histopathologic findings (RCD code: III‐1B.5a)
The anthracycline anticancer drug Doxorubicin (Adriamycin) is an effective and frequently used chemotherapeutic agent for various malignancies. The use of doxorubicin is limited by its major adverse effect, cardiotoxicit...
Cardiac sarcoidosis – management and prognosis (RCD code: III‑3A.3)
Sarcoidosis is a systemic, granulomatous disease of unknown etiology. Cardiac involvement in the course of sarcoidosis occurs in 5% of patients. However, about 25% of patient with systemic/pulmonary sarcoidosis might pre...